ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
A Dual-Response DNA Origami Platform for Imaging and Treatment of Sepsis-Associated Acute Kidney Injury.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- From Blueprint to Breakthrough: How Far Can We Fold DNA Origami for Nano-Enabled Technologies?JACS Au · 2026Review
- Transition from acute kidney injury to chronic kidney disease: molecular mechanisms and therapeutic interventions.Molecular biomedicine · 2026Review
- Antimicrobial Peptide Nanoassemblies: Design, Response Mechanisms, and Biomedical Applications.Molecules (Basel, Switzerland) · 2026Review
- Dual-responsive zwitterionic hydrogel microneedle patch for the on-site detection of two alzheimer's disease - related miRNAs.Journal of nanobiotechnology · 2026Article
- Targeted Sirtuin 3 Activation by Biomimetic Black Phosphorus Nanosheets Mitigates Sepsis-Induced Acute Kidney Injury through Yeast Mitochondrial Escape 1-Like 1 Deacetylation.Biomaterials research · 2026Article
- Kidney-targeted nanoplatforms: Strategies and applications.Theranostics · 2026Review
- Burns: The "Fuse" That Ignites Organ Crisis - A Narrative Review of Mechanisms and Crosstalk in Post-Burn MODS.Journal of inflammation research · 2026Review
- Inflammation, cell death, and lncRNAs: unraveling the mechanisms of sepsis-associated acute kidney injury.Frontiers in immunology · 2026Review
- Recent Advances in Functionalized Gold Nanoprobes for Photoacoustic Imaging Analysis of Diseases.Sensors (Basel, Switzerland) · 2025Review
- DNA Origami-Based CD44-Targeted Therapy Silences Stat3 Enhances Cartilage Regeneration and Alleviates Osteoarthritis Progression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Unlocking new frontiers: DNA nanotechnology's impact on acute kidney injury diagnosis and treatment.Nanomedicine (London, England) · 2025Review
- Single-Molecule Detection of Optical Signals Using DNA-Based Plasmonic Nanostructures.Biosensors · 2025Review
- A Dual-Response DNA Origami Platform for Imaging and Treatment of Sepsis-Associated Acute Kidney Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
Current diagnostics for sepsis-associated acute kidney injury (SA-AKI) detect kidney damage only at advanced stages, limiting opportunities for timely intervention. A DNA origami-based nanoplatform is developed for the early diagnosis and treatment of SA-AKI. Modified with a fluorophore (Cy5) and quencher (BHQ3), the DNA origami remains nonfluorescent under normal conditions. During SA-AKI, elevated microRNA-21 triggers a strand displacement reaction that restores the fluorescence signal, enabling real-time detection. Additionally, the photoacoustic changes of BHQ3, driven by different excretion rates of the nanostructure and released DNA strands, enable dual-mode imaging, enhancing diagnostic accuracy. Therapeutically, DNA origami scavenges reactive oxygen species and, when conjugated with the antimicrobial peptide Leucine-Leucine-37 (LL-37), exhibits bactericidal effects. This combination boosts survival rates by 80% in SA-AKI models. This dual-response nanoplatform integrates precise imaging and targeted therapy, offering a powerful strategy for SA-AKI management and advancing applications of DNA origami in precision nanomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.